The sale of a minority stake of its U.S. Biopharma business by means of an initial public offering (IPO) would raise capital to strengthen the Group’s balance sheet, reduce debt and support investment in its strategic growth priorities, while allowing Grifols to maintain majority ownership of its U.S. Biopharma business The proposed transaction reinforces Grifols’ self-sufficiency vision ...
Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.
Descubre las innovadoras soluciones biofarmacéuticas y sanitarias integrales de Grifols centradas en el paciente.
Explore Grifols Poland, a leader in biotechnology and healthcare, dedicated to improving patient lives through innovative therapies and high-quality services.
Grifols is a global healthcare company that has enhanced the health and well-being of people around the world.
Join Grifols to create a lasting impact with your career. Explore opportunities that allow you to contribute to life-saving solutions and innovate for a healthier future.
Grifols is also a leader in transfusion medicine, helping ensure the safety of the world’s blood supply. In addition, we provide biological materials, including plasma, for life-science research and further manufacturing, and the company has a comprehensive portfolio of tools, information and services that enable hospitals to efficiently ...
We trace our roots back to 1909 when Dr. Josep Antoni Grifols i Roig founded the first analysis laboratory in Barcelona: Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos.
Contact Grifols for inquiries and support. Our team is here to assist you with information and resources tailored to your needs.
Explore Grifols France for cutting-edge pharmacovigilance and comprehensive medical information to enhance patient safety and treatment outcomes.
Recent sales data reveals a robust recovery in luxury watch sales. In 2023, Europe accounted for approximately 35% of global luxury watch sales. North America followed closely with a 25% market share, while the Asia-Pacific region represented 20%.